Litcius/Paper detail

Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?

Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis, Ramzi Ajjan, Kalliopi Kotsa

2020Journal of Diabetes Science and Technology15 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Pandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineDiabetes mellitusVirologyInternal medicineEndocrinologyInfectious disease (medical specialty)DiseaseOutbreakDiabetes Treatment and ManagementNeuroendocrine Tumor Research AdvancesPotassium and Related Disorders
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable? | Litcius